Healthcare
Champions Oncology Inc(CSBR)
Live Price
Offline$6.42
+12.24% today
1Y Change
-21.65%
Window
Jun 27, 2025 โ Jun 25, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +13.5%
- EPS Growth
- +163.0%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 27, 2025 โ Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Champions Oncology Inc (CSBR) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $6.42 and down 21.6% across the available one-year price window (Jun 27, 2025 โ Jun 25, 2026). Baseline metrics include revenue growth of +13.5%, EPS growth of +163.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.5%, EPS +163.0%, free cash flow +200.3% with operating margin -3.8% and ROIC -23.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Stock Foundry combines CSBR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.5% vs +7.6% peer median
Operating Margin
Below sector median
-3.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 12, 2026 with an EPS surprise of -122.2% and a revenue surprise of -0.3%.
The operating story is still moving forward
Revenue is running at +13.5% and EPS at +163.0%, with operating margin around -3.8%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 16, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 12, 2026 | -122.2% | +6.3% | +8.0% | +0.2% |
2025 Dec 15, 2025 | -75.0% | -13.7% | -7.1% | -7.9% |
2025 Sep 15, 2025 | -400.0% | -16.0% | -18.7% | -21.6% |
Benchmark Edge
CSBR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSBR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSBR Max Drawdown
-36.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSBR and SPY.
Company Overview
Champions Oncology Inc
NASDAQ
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.
- Leadership
- Mr. Robert Brainin
- Employees
- 213
- Street Address
- One University Plaza, Suite 307
- Mailing
- Hackensack, NJ, 07601
- Region
- Hackensack, NJ, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.4
- Price/Book
- 19.4
Growth
- Revenue
- +13.5%
- EPS
- +163.0%
- Free Cash Flow
- +200.3%
Profitability
- Gross Margin
- 43.4%
- Operating Margin
- -3.8%
- Net Margin
- -3.9%
- ROE
- -57.2%
- ROIC
- -23.2%
Balance Sheet
- Debt/Equity
- 1.17
- Current Ratio
- 0.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.